Gabapentin
Product Images NDC 10544-186

6 FDA label images from Blenheim Pharmacal, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 10544-186). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label (10544 186 30 53746 102 05)

Bottle Label (10544 186 30   53746 102 05)
Gabapentin Capsules, 300 mg, in a blister pack labeled by Blenheim Pharmacal, Inc. The label displays the product NDC 10544-186-30 and indicates that the pack contains 30 capsules. It is marked Rx Only with storage instructions to keep at controlled room temperature of 20-25°C (68-77°F), with permitted excursions between 15-30°C (59-86°F). Lot number and expiration date fields are visible but not filled in.*
FDA Label Image

Dc2d0eb8-figure-01 (Dc2d0eb8 Figure 01)

Dc2d0eb8-figure-01 (Dc2d0eb8 Figure 01)
Chemical structure of gabapentin, showing a cyclohexane ring with side chains including an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*
FDA Label Image

Dc2d0eb8-figure-02 (Dc2d0eb8 Figure 02)

Dc2d0eb8-figure-02 (Dc2d0eb8 Figure 02)
A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin 3600 mg/day. The graph shows a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin demonstrates a decreasing pain score trend, while placebo remains relatively stable. Statistical significance (p < 0.01) is noted at various points for Gabapentin.*
FDA Label Image

Dc2d0eb8-figure-03 (Dc2d0eb8 Figure 03)

Dc2d0eb8-figure-03 (Dc2d0eb8 Figure 03)
A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day. The x-axis represents weeks including a 4-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing trend in pain scores compared to placebo throughout the study.*
FDA Label Image

Dc2d0eb8-figure-04 (Dc2d0eb8 Figure 04)

Dc2d0eb8-figure-04 (Dc2d0eb8 Figure 04)
A bar chart depicting the percentage of responders at the endpoint in two clinical studies for Gabapentin (GBP) at doses 3600 mg, 1800 mg, and 2400 mg, compared to placebo (PBO). Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% responders for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*
FDA Label Image

Dc2d0eb8-figure-05 (Dc2d0eb8 Figure 05)

Dc2d0eb8-figure-05 (Dc2d0eb8 Figure 05)
A scatter plot comparing difference percentage values against daily dose in mg for Gabapentin across three studies labeled a, b, and c. The x-axis represents daily doses ranging from 600 to 1800 mg, while the y-axis shows difference percentages from 2 to 22%. Each study is represented by distinct markers: study a by black squares, study b by gray squares, and study c by white squares, with respective values plotted along the dose range.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.